BookPDF Available

Bangladesh National Health Accounts 1997-2015 (BNHA-V)

  • September 2018
  • Publisher: Health Economics Unit, Health Services Division, Ministry of Health and Family Welfare
Authors:
Ahmed Mustafa at Health Economics Unit
Ahmed Mustafa
  • Health Economics Unit
A F. M. Azizur Rahman
A F. M. Azizur Rahman
A F. M. Azizur Rahman
  • This person is not on ResearchGate, or hasn't claimed this research yet.
Najmul Hossain
Najmul Hossain
Najmul Hossain
  • This person is not on ResearchGate, or hasn't claimed this research yet.
Tahmina Begum
Tahmina Begum
Tahmina Begum
  • This person is not on ResearchGate, or hasn't claimed this research yet.
Download full-text PDFDownload full-text PDF
Read full-text
Download citation

Figures

Figures - uploaded by Ahmed Mustafa
Author content
All figure content in this area was uploaded by Ahmed Mustafa
Content may be subject to copyright.
BNHA 1997-20
15.pdf
Content uploaded by Ahmed Mustafa
Author content
All content in this area was uploaded by Ahmed Mustafa on Mar 10, 2019
Content may be subject to copyright.
BNHA 1997-20
15.pdf
Content uploaded by Ahmed Mustafa
Author content
All content in this area was uploaded by Ahmed Mustafa on Feb 15, 2019
Content may be subject to copyright.
A preview of the PDF is not available
... 7 According to the findings of the Bangladesh National Health Accounts (BNHA-V) study, the dengue situation in Bangladesh is causing an economic burden in our health sector, just as it is in other lower and middleincome countries. 8 Between 2012 and 2019, the largest dengue cases were reported in Dhaka, the capital and most populous city in Bangladesh, with a population of almost 16 million. 9,10 According to several studies, recovery from DENV infection is associated with permanent immunity against that serotype, whereas infection with different serotypes results in only transitory and partial protection, increasing the risk of severe dengue. ...
Recent outbreak of dengue in Bangladesh: A threat to public health
Article
Full-text available
  • Apr 2023
Background and Aims: The dengue virus is widespread throughout Bangladesh and significantly contributes to morbidity and mortality. One effective method for preventing further dengue epidemics is to reduce mosquito breeding at the most opportune period each year. This study aims to determine dengue prevalence in 2022 by comparing previous years' data and estimating the period of this disease's most significant incidence. Methods: From the beginning of 2008–December 15, 2022, we looked at the monthly reports of cases made to the Bangladesh Institute of Epidemiology, Disease Control, and Research. Results: According to our findings, there were 61089 confirmed dengue cases in 2022, with 269 fatalities‐ the highest annual death toll for this disease since 2000. Almost onethird (32.14%) of all dengue deaths in Bangladesh occurred in 2022 (1 January–15 December), highlighting the severity of the threat posed by this disease in the coming year. Furthermore, we observe that the months in the second half of any year in Bangladesh are the most at risk for dengue transmission. In 2022, Dhaka city and Chittagong are hit the hardest (incidence: 63.07% vs. 14.42%; morality: 63.34% vs. 24.16%), showing the relevance of population density in spreading this fatal disease. Conclusion: Statistics show an increase in dengue cases every day, and the year 2022 will be marked as the peak of the disease's death prevalence. Both the individuals and the government of Bangladesh need to take action to reduce the dissemination of this epidemic. If not, the country will soon be in great peril.
View
... This may be because of prolonged symptom onset to hospital arrival time [15]. Revascularization procedures are frequently delayed in Bangladesh, where the majority (67%) of healthcare expenditure is out-of-pocket [40]. Most revascularization procedures are often delayed during which patients and family secure financial resources for the intervention, a practice not compatible with treatment guidelines for acute MI of the European Society of Cardiology [41]. ...
In-hospital and 30-day major adverse cardiac events in patients referred for ST-segment elevation myocardial infarction in Dhaka, Bangladesh
Article
Full-text available
Background There is a paucity of data regarding acute phase (in-hospital and 30-day) major adverse cardiac events (MACE) following ST-segment elevation myocardial infarction (STEMI) in Bangladesh. This study aimed to document MACE during the acute phase post-STEMI to provide information. Methods We enrolled STEMI patients of the National Institute of Cardiovascular Disease, Dhaka, Bangladesh, from August 2017 to October 2018 and followed up through 30 days post-discharge for MACE, defined as the composite of all-cause death, myocardial infarction, and coronary revascularization. Demographic information, cardiovascular risk factors, and clinical data were registered in a case report form. The Cox proportional hazard model was used for univariate and multivariate analysis to identify potential risk factors for MACE. Results A total of 601 patients, mean age 51.6 ± 10.3 years, 93% male, were enrolled. The mean duration of hospital stay was 3.8 ± 2.4 days. We found 37 patients (6.2%) to experience an in-hospital event, and 45 (7.5%) events occurred within the 30 days post-discharge. In univariate analysis, a significantly increased risk of developing 30-day MACE was observed in patients with more than 12 years of formal education, diabetes mellitus, or a previous diagnosis of heart failure. In a multivariate analysis, the risk of developing 30-day MACE was increased in patients with heart failure (hazard ratio = 4.65; 95% CI 1.64–13.23). Conclusions A high risk of in-hospital and 30-day MACE in patients with STEMI exists in Bangladesh. Additional resources should be allocated providing guideline-recommended treatment for patients with myocardial infarction in Bangladesh.
View
... This may be because of prolonged symptom onset to hospital arrival time [15]. Revascularization procedures are frequently delayed in Bangladesh, where the majority (67%) of healthcare expenditure is out-of-pocket [35]. Most revascularization procedures are scheduled post-discharge during which time patients and family secure nancial resources for the intervention, a practice not compatible with treatment guidelines for acute MI of the European Society of Cardiology [36]. ...
In-hospital and 30-day major adverse cardiac events in patients referred for ST-segment elevation myocardial infarction in Dhaka, Bangladesh
Preprint
Full-text available
  • Oct 2020
Background: There is a paucity of data regarding acute phase (in-hospital and 30-day) major adverse cardiac events (MACE) following ST-segment elevation myocardial infarction (STEMI) in Bangladesh. This study aimed to document MACE during the acute phase post-STEMI to provide information. Methods: We enrolled STEMI patients of the National Institute of Cardiovascular Disease, Dhaka, Bangladesh, from August 2017 to October 2018 and followed up through 30 days post-discharge for MACE, defined as the composite of total death, myocardial infarction, and coronary revascularization. Demographic information, cardiovascular risk factors, and clinical data were registered in a case report form. The Cox proportional hazard model was used for univariate and multivariate analysis to identify potential risk factors for MACE. Results: A total of 601 patients, mean age 51.6±10.3 years, 93% male, were enrolled. The mean duration of hospital stay was 3.8±2.4 days. We found 37 patients (6.2%) to experience an in-hospital event, and 45 (7.5%) events occurred within the 30 days post-discharge. In univariate analysis, a significantly increased risk of developing 30-day MACE was observed in patients with more than 12 years of formal education, diabetes mellitus, or a previous diagnosis of heart failure. In a multivariate analysis, the risk of developing 30-day MACE was increased in patients with heart failure (hazard ratio = 4.65; 95% CI, 1.64–13.23). Conclusions: A high risk of in-hospital and 30-day MACE in patients with STEMI exists in Bangladesh. Additional resources should be allocated providing guideline-recommended treatment for patients with myocardial infarction in Bangladesh.
View
Total Health Expenditure by Provider and Revenue of the Financing Schemes
  • Jan 2009
Total Annex Table 37: Total Health Expenditure by Provider and Revenue of the Financing Schemes, 2009 and 2010 (Million Taka) 2009